Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Brief Summary: The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.


Options:
A: Arm Label: Surgery + HIPEC + Systemic Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Oxaliplatin, Drug: Irinotecan, Drug: 5-Fluorouracil, Drug: Leucovorin, Procedure: Gastrectomy and/or metastasectomy | Arm Label: Systemic Chemotherapy Alone; Type: EXPERIMENTAL; Interventions: Drug: Oxaliplatin, Drug: Irinotecan, Drug: 5-Fluorouracil, Drug: Leucovorin | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: PROCEDURE; Name: Gastrectomy and/or metastasectomy; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy
B: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Capecitabine, Drug: Cisplatin, Drug: 5-fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Bevacizumab, Placebo
C: Arm Label: Standard taxane therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Taxane | Arm Label: trastuzumab emtansine 2.4 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Arm Label: trastuzumab emtansine 3.6 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Intervention Type: DRUG; Name: Taxane; Assigned to Arm(s): Standard taxane therapy | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 3.6 mg | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 2.4 mg
D: Arm Label: Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): Ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Placebo, Ramucirumab

Answer: D